Repetitive Strain Injury (RSI) Treatment Market Set for Significant Growth, Expected to Reach $2.94 Billion by 2028

June 25, 2024 01:48 PM BST | By EIN Presswire
 Repetitive Strain Injury (RSI) Treatment Market Set for Significant Growth, Expected to Reach $2.94 Billion by 2028
Image source: EIN Presswire

LONDON, GREATER LONDON, UK, June 25, 2024 /EINPresswire.com/ -- Global Repetitive Strain Injury (RSI) Treatment Market Set for Significant Growth, Expected to Reach $2.94 Billion by 2028
The repetitive strain injury (RSI) treatment market is projected to grow from $1.99 billion in 2023 to $2.18 billion in 2024, at a CAGR of 9.1%. Despite challenges such as increasing occupational risks and the need for ergonomic awareness, the market is anticipated to reach $2.94 billion by 2028, driven by the rise in remote work, integration of preventive measures, and increased healthcare awareness.

Increase in Musculoskeletal Disorders Drives Market Growth
An increase in musculoskeletal disorders (MSD) in the workplace is a significant factor contributing to the growth of the RSI treatment market. Musculoskeletal disorders, including RSI, encompass a range of conditions affecting the muscles, bones, tendons, ligaments, and other parts of the musculoskeletal system. These disorders often result from repetitive movements, awkward postures, and poor ergonomics in the workplace. For instance, in December 2022, Osteopaths for Industry (OFI) reported that 477,000 workers in the UK had work-related musculoskeletal disorders in 2021/22, resulting in the loss of 7.3 million working days. Therefore, the increase in musculoskeletal disorders in the workplace supports the growth of the RSI treatment market.

Explore comprehensive insights into the global repetitive strain injury (RSI) treatment market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample_request?id=13127&type=smp

Key Players and Market Trends
Major companies operating in the repetitive strain injury (RSI) treatment market include Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., and Eli Lilly and Co Ltd. These companies are focusing on advanced technology to provide reliable customer service. For example, Hydro Physio, a UK-based aquatic therapy treadmill manufacturing company, launched a new hydrotherapy system in January 2023. The technology, which includes a treadmill chamber, an entryway, and built-in water management technology, aims to help with osteoarthritis, recovery from surgery, weight loss, pain relief, and stress reduction.
The major trend in the RSI treatment market is the adoption of advanced technology, such as hydrotherapy systems with built-in water management technology. These systems treat people with particular diseases or injuries by making them exercise in water, offering remedies for private, hygienic aquatic therapeutic rooms. This innovation enhances general well-being and lessens the stress on painful joints.

Segments:
•By Type: Carpal Tunnel Syndrome, Bursitis, Tennis Elbow, Other Types
•By Treatment: Medication, Physiotherapy, Steroid Injections, Surgery, Other Treatments
•By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Geographical Insights: North America Leading the Market
North America was the largest region in the RSI treatment market in 2023. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities.

Access the complete report for an in-depth analysis of the global repetitive strain injury (RSI) treatment market: https://www.thebusinessresearchcompany.com/report/repetitive-strain-injury-rsi-treatment-global-market-report

Repetitive Strain Injury (RSI) Treatment Global Market Report 2024 from TBRC covers the following information:
•Market size data for the forecast period: Historical and Future
•Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
•Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Repetitive Strain Injury (RSI) Treatment Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on repetitive strain injury (RSI) treatment market size, repetitive strain injury (RSI) treatment market drivers and trends, repetitive strain injury (RSI) treatment market major players, competitors' revenues, market positioning, and market growth across geographies. The repetitive strain injury (RSI) treatment market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Neuralgia Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Pituitary Dwarf Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Difficile-Associated Diarrhea Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/difficile-associated-diarrhea-treatment-global-market-report

About The Business Research Company
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next